Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.

Bhagwat, Neha; Koppikar, Priya; Keller, Matthew; Marubayashi, Sachie; Shank, Kaitlyn; Rampal, Raajit; Qi, Jun; Kleppe, Maria; Patel, Hardik J; Shah, Smit K; Taldone, Tony; Bradner, James E; Chiosis, Gabriela; Levine, Ross L.
Blood; 123(13): 2075-83, 2014 Mar 27.
Artigo em Inglês | MEDLINE | ID: mdl-24470592